{"product_id":"stem-cell-manufacturing-market-by-product-consumables-instruments-stem-cell-lines-application-research-clinical-cell-tissue-banking-end-user-region-north-america-europe-apac-latin-america-mea-global-forecast-to-2028","title":"Stem Cell Manufacturing Market by Product (Consumables, Instruments, Stem Cell Lines), Application (Research, Clinical, Cell Tissue \u0026 Banking), End User, Region (North America, Europe, APAC, Latin America, MEA) - Global Forecast to 2028","description":"\u003cp\u003eStem Cell Manufacturing Market by Product (Consumables, Instruments, Stem Cell Lines), Application (Research, Clinical, Cell Tissue \u0026amp; Banking), End User, Region (North America, Europe, APAC, Latin America, MEA) - Global Forecast to 2028\u003c\/p\u003e\n\n\u003cp\u003eThe stem cell manufacturing market is projected to reach USD 21.8 billion by 2028 from USD 12.7 billion in 2023, at a CAGR of 11.3% during the forecast period. The major factors driving the increasing prevalence of genetic diseases and increasing regulatory approvals on stem cell therapies are expected to propel the growth of the market. However, the high costs of research and manufacturing are expected to restrain market growth to a certain extent.\u003c\/p\u003e\n\n\u003cp\u003eThe stem cell manufacturing market has been segmented based on product, application, end-user, and region.\u003c\/p\u003e\n\n \u003cp\u003e“By-products, the consumables segment accounted for the largest share of the stem cell manufacturing market.”\u003c\/p\u003e\n\n\u003cp\u003eBased on products, the stem cell manufacturing market is categorized into consumables, instruments, and stem cell lines. The consumables segment dominated the market in 2023, owing to rising demand for stem cell-based research, increasing government funding and initiatives, and the rising number of collaborations between academic institutions and pharmaceutical companies has led to a higher growth rate for products in the stem cell manufacturing market.\u003c\/p\u003e\n\n\u003cp\u003e“By application, research application segment accounted for the largest share in the stem cell manufacturing market.”\u003c\/p\u003e\n\n\u003cp\u003eBased on application, the stem cell manufacturing market is segmented into research applications, clinical applications, and cell \u0026amp; tissue banking applications. In 2023, the research application segment accounted for a larger share of the stem cell manufacturing market. Growth in this market segment can be attributed to a rising focus on stem cell cytology \u0026amp; pathophysiology research, growing awareness about the therapeutic potency of stem cells among researchers and healthcare professionals, growing public-private funding to support stem cell product development and commercialization, and technological advancements related to the effective production scale-up for stem cell products.\u003c\/p\u003e \n\n\u003cp\u003e“North America: the largest share of the stem cell manufacturing market”\u003c\/p\u003e\n\n\u003cp\u003eNorth America accounted for the largest share of the stem cell manufacturing market. The large share of the North American region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in stem cell research. The presence of top academic institutions and private companies in North America with dedicated stem cell research programs and expertise has contributed to the growth of the stem cell manufacturing market.\u003c\/p\u003e\n\n\u003cp\u003e“Asia Pacific: The fastest-growing region in the stem cell manufacturing market.”\u003c\/p\u003e\n\n\u003cp\u003eThe Asia Pacific stem cell manufacturing market is projected to grow at the highest CAGR during the forecast period. This is attributed to the increasing demand for personalized medicine and advancements in stem cell-based therapies. Another key driver for the Asia Pacific stem cell manufacturing market is the region's large and rapidly increasing population.\u003c\/p\u003e \n\n\u003cp\u003eThe primary interviews conducted for this report can be categorized as follows:\u003c\/p\u003e\n\n\u003cp\u003eBy Respondent: Supply Side- 63% and Demand Side- 37%\u003c\/p\u003e\n\n\u003cp\u003eBy Designation: C Level Executives - 45%, Director Level- 30%, and Others - 25%\u003c\/p\u003e\n\n\u003cp\u003eBy Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America - 10%, and Middle East Africa- 5%\u003c\/p\u003e\n\n\u003cp\u003eProminent  Players\u003c\/p\u003e\n\n\u003cp\u003eThermo Fisher Scientific, Inc. (US)\u003c\/p\u003e\n\n\u003cp\u003eMerck KGaA (Germany)\u003c\/p\u003e\n\n\u003cp\u003eLonza Group (Switzerland)\u003c\/p\u003e\n\n\u003cp\u003eDanaher Corporation (US)\u003c\/p\u003e\n\n\u003cp\u003eSartorius AG (Germany)\u003c\/p\u003e\n\n\u003cp\u003eBecton, Dickinson, and Company (US)\u003c\/p\u003e\n\n\u003cp\u003eEppendorf AG (Germany)\u003c\/p\u003e\n\n\u003cp\u003eCorning Inc. (US)\u003c\/p\u003e\n\n\u003cp\u003eBio-Rad Laboratories (US)\u003c\/p\u003e\n\n\u003cp\u003eTakara Bio Group (Japan)\u003c\/p\u003e\n\n\u003cp\u003eFujifilm Holdings Corporation (Japan)\u003c\/p\u003e\n\n\u003cp\u003eGetinge AB (Sweden)\u003c\/p\u003e\n\n\u003cp\u003eTerumo Corporation (Japan)\u003c\/p\u003e\n\n\u003cp\u003eBio-Techne Corporation (US)\u003c\/p\u003e\n\n\u003cp\u003eHiMedia Laboratories (India)\u003c\/p\u003e\n\n\u003cp\u003eStemCell Technologies, Inc. (Canada)\u003c\/p\u003e\n\n\u003cp\u003eMiltenyi Biotec GmBH (Germany)\u003c\/p\u003e\n\n\u003cp\u003ePromoCell (Germany), Anterogen Co. Ltd. (South Korea)\u003c\/p\u003e\n\n\u003cp\u003eCellGenix GmBH (India)\u003c\/p\u003e\n\n\u003cp\u003ePluristem Therapeutics Inc. (Israel)\u003c\/p\u003e\n\n\u003cp\u003eDaiichi Sankyo (Japan)\u003c\/p\u003e\n\n\u003cp\u003eOrganogenesis Holdings Inc. (US)\u003c\/p\u003e\n\n\u003cp\u003eVericel Corporation (US)\u003c\/p\u003e\n\n\u003cp\u003eAmerican Cryostem Corporation (US)\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage:\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a detailed picture of the stem cell manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (Consumables (culture media, and other consumables), instruments (Bioreactors \u0026amp; Incubators, cell sorters, and other instruments), and stem cell lines (hematopoietic stem cells, mesenchymal stem cells, induced pluripotent stem cells, embryonic stem cells, neural stem cells, and multipotent adult progenitor stem cells), application(research applications (life science research, and drug discovery and development), clinical applications (allogeneic stem cell therapy, and autologous stem cell therapy), and cell \u0026amp; tissue banking applications), and end-user (hospitals \u0026amp; surgical centers, pharmaceutical \u0026amp; biotechnology companies, cell \u0026amp; tissue banks, academic institutes, research laboratories, and CROs, and other end users) and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.\u003c\/p\u003e\n\n\u003cp\u003eKey Benefits of Buying the Report:\u003c\/p\u003e\n\n\u003cp\u003eThe report will help market leaders\/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell manufacturing market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides insights on the following pointers:\u003c\/p\u003e\n\n\u003cp\u003eAnalysis of key drivers (growing venture capital investments in stem cell research, increasing awareness about the therapeutic potency of stem cell products, and technological advancements in stem cell manufacturing), restraints (significant operational costs associated with stem cell manufacturing and banking), opportunities (development of new vaccine and treatment of genetic diseases in Asia Pacific region, government initiatives to boost the biotechnology and biopharmaceutical industries, and increased market focus on mesenchymal stem cells and induced pluripotent stem cells), and challenges (technical limitations associated with manufacturing scale-up, and socio-ethical concerns related to the use of allogeneic and human embryonic stem cells) influencing the growth of the stem cell manufacturing market.\u003c\/p\u003e\n\n\u003cp\u003eProduct Development\/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the stem cell manufacturing market.\u003c\/p\u003e \n\n\u003cp\u003eMarket Development:  Comprehensive information about lucrative markets- the report analyses the stem cell manufacturing market across varied regions.\u003c\/p\u003e\n\n\u003cp\u003eMarket Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the stem cell manufacturing market.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Merck KGaA (Germany), Lonza Group (Switzerland), and Danaher Corporation (US), among others, in the stem cell manufacturing market strategies. The report also helps stakeholders understand the pulse of the stem cell manufacturing market and provides them with information on key market drivers, restraints, challenges, and opportunities.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"July, 2023 \/ 300 Pages \/ MCW16231435","offer_id":47647314805042,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/stem-cell-manufacturing-market-by-product-consumables-instruments-stem-cell-lines-application-research-clinical-cell-tissue-banking-end-user-region-north-america-europe-apac-latin-america-mea-global-forecast-to-2028","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}